We report a novel mechanism of a CDH1 splicing mutation in a patient with signet ring cell carcinoma of the stomach. A 27-year-old man complaining of aggravated dyspepsia was diagnosed with signet ring cell carcinoma. Both his father and uncle had died of stomach cancer at a young age. DNA sequencing analysis of the CDH1 gene revealed a splice site mutation (c.833-2A＞G). By RNA/cDNA sequencing analysis, CDH1 c.833-2A＞G generated a new acceptor site within intron 6, causing the insertion of a 79-bp intronic sequence between exon 6 and 7 (r.833-79_833-1ins), and resulting in a frame shift. E-cadherin immunohistochemical staining revealed a loss of CDH1 expression. This study reveals the disease-causing mechanism of this splicing mutation, and emphasizes the need for functional studies using RNA samples for the accurate interpretation of detected splicing variant. This is the first reported case of a CDH1 mutation in a Korean patient. [BMB reports 2011; 44(11): 725-729]
INTRODUCTION
Hereditary diffuse gastric cancer (HDGC) is defined by the International Gastric Cancer Linkage Consortium (IGCLC) as 2 or more cases of diffuse gastric cancer in first-or second-degree relatives, with at least one diagnosed before the age of 50 years, or 3 or more pathologically documented cases of diffuse gastric cancer in first-or second-degree relatives of any age (1) . Although only a few gastric cancers are hereditary, the identification of such cases may provide valuable information for genetic counseling, genetic testing for gastric cancer susceptibility, and gastric cancer risk reduction strategies for as-yet unaffected family members (1) . The vast majority of CDH1 gene mutation carriers (＞90%) already exhibit microscopic intramucosal disease by prophylactic total gastrectomy (2) . One-third of all HDGC families harbor a germline mutation of the CDH1 gene, which encodes E-cadherin, a cell-to-cell adhesion protein that plays a fundamental role in the maintenance of cell differentiation and the normal architecture of epithelial tissues. E-cadherin deficiency provides an obvious explanation for the diffuse, scattered growth of HDGC tumors, as this protein is the central component of epithelial cell-to-cell adhesion (3, 4) . We report herein a novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma of the stomach. This study reveals the disease-causing mechanism of this splicing mutation (based on sequencing RNA/ cDNA from the patient) and emphasizes the need for functional studies using RNA samples for the accurate interpretation of any detected splicing variant by DNA sequencing. In addition, to our knowledge, this is the first reported case of a CDH1 mutation in a Korean patient.
Subject
A 27-year-old Korean man had been complaining of dyspepsia for 7 years, and had symptoms of aggravated epigastric pain and indigestion for 2 months. Physical examination revealed no significant findings. He was an ex-smoker (had quit 8 years prior to examination) and had no underlying diseases such as diabetes or hypertension. A family history of stomach cancer was evident; his father and uncle died at the ages of 33 and 41, respectively, from the disease (Fig. 1) . A 2.5-cm hyperemic, friable, nodular lesion was observed on the angle of his stomach by gastroendoscopy, suggesting advanced gastric cancer. In addition, chronic active Helicobacter pylori (H. pylori) gastritis was found. An endoscopic biopsy was performed, and he was diagnosed with signet ring cell carcinoma. Computed tomography revealed no obvious stomach wall thickening and no evidence of lymph node or distant metastasis. The levels of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 72-4 (CA72-4) were all within normal limits. The nodular lesion on the stomach angle http://bmbreports.org was surgically removed by curative total radical gastrectomy. The pathological diagnosis was advanced gastric cancer without lymphatic or venous invasion, indicating surgical stage 1B (T2aNOMO) (5) . Microscopic examination revealed signet ring cell carcinoma. Immunohistochemical staining using an unconjugated E-cadherin monoclonal antibody (mouse anti-ECadherin; Invitrogen, Carlsbad, CA, USA) demonstrated markedly decreased expression of E-cadherin in tumor cells compared to foveolar epithelial cells (Fig. 2) . Although the histologic diagnosis of cancer was not revealed in the proband's father and uncle, their young age at cancer development (33 and 41 years in the father and the uncle, respectively), and the signet ring cell-type histology in the proband suggested an autosomal dominant genetic trait and HDGC. Thus, we searched for a causative mutation in the CDH1 gene.
RESULTS

Sequence analysis
Direct DNA sequencing of the CDH1 gene revealed a heterozygous A to G transition at cDNA position 833-2 (c.833-2A ＞ G), which is a splice site mutation (Fig. 3B ). We performed further analysis using a sample of the patient's RNA/cDNA to confirm the splicing defect. The reverse transcription-polymerase chain reaction (RT-PCR) products consisted of the expected band size and a larger band (Fig. 3A) . Direct sequencing of the PCR products yielded dual peaks at the beginning of the exon 6/7 junction in both the forward and reverse reactions (Fig. 3B ). The mutant sequence, which had a low peak height, was identical to the 79-bp sequence of the 3' end of intron 6 when aligned with the reference sequence (NM_004360.3) of the CDH1 gene from genomic databases such as those at UCSC (University of California Santa Cruz) (http://genome.ucsc.edu/) and Ensemble (http://www.ensembl.org/) ( Fig. 3B and C) . We found that CDH1 c.833-2A＞G generated a new acceptor site within intron 6, causing the insertion of a 79-bp intronic sequence between exon 6 and 7 (r.833-79_833-1ins), and resulting in a frame shift (Fig. 3C) . There was no mutation in genomic DNA samples isolated from 96 normal healthy volunteers, which suggested the presence of a mutation rather than polymorphism.
Bioinformatic analysis
The results of the bioinformatic analysis are summarized in Table 1 . All 9 algorithms predicted the splice defect. In addition, the new potential predicted splice sites were consistent with the in vivo results obtained from all algorithms.
DISCUSSION
We report a first case of CDH1 mutation in a Korean patient with signet ring cell carcinoma of the stomach. Previously, Yoon et al. A new acceptor splice site was generated at position c.833-81 within intron 6, marked by "ag". The last 9-bp sequence (CTC TTC TAG) of exon 6 is identical to that of intron 6, yielding homozygous peaks on the chromatogram (bold font in Fig. 3B and 3C ).
using denaturing high-performance liquid chromatography (DHPLC) and automatic sequencing by authors from the same laboratory did not reveal any CDH1 germline mutation in these 2 families. They concluded that the previous incorrect results may have originated from experimental artifacts generated during the PCR single-strand conformation polymorphism (SSCP) or cloning-sequencing steps (7) . Although gastric cancer is the second most common type of cancer worldwide, germline mutations in CDH1 are found in only 1-3% of all gastric cancers (8) . In addition, inactivating germline CDH1 mutations occur less frequently in countries with high sporadic gastric cancer rates, such as Japan and Korea (4). This observation may be related to the obscured identification of families with inherited susceptibilities or population frequencies with low-penetrance alleles (4). This study, based on sequencing of RNA/cDNA from the patient, demonstrates the pathogenic mechanism of the CDH1 c.833-2A＞G splicing mutation. We found that this mutation generated a new acceptor site at position c.833-81 within intron, causing the insertion of a 79-bp intronic sequence between exon 6 and 7 (r.833-79_ 833-1ins) and resulting in a frame shift. This result emphasizes the need for functional studies using RNA samples for the accurate interpretation of any splicing variant detected by DNA sequencing. Although the c.833-2A＞G mutation was previously reported in a symptomatic patient with diffuse gastric cancer (9), the disease-causing mechanism of this splicing mutation was not described. Analyses at the mRNA level are essential for detecting novel or unclassified variants that induce splicing alterations; however, such analyses are not always suitable as a routine laboratory procedure. The reliability and accuracy of predicting splicing alterations are valuable, making in silico splicing prediction useful. We compared 9 different algorithms for the novel CDH1 c.833-2A＞G variant. All 9 algorithms predicted this variation as deleterious. The predicted new potential splice sites of all of the algorithms were consistent with the in vivo result ( WT: wild-type, -: below the threshold. Table 1 . In silico analysis of the CDH1 c.833-2A＞G variant using various splicing prediction programs variants (10) . E-cadherin plays a central role in the maintenance of cell polarity, and its loss during tumorigenesis is associated with poorly differentiated cancers, often with signet ring cell morphology (4). HDGC initiation requires somatic downregulation of the second CDH1 allele, which in most cases, is caused by DNA promoter hypermethylation (4). Transient episodes of H. pylori infection or gastritis are sufficient to provoke stable DNA methylation (4) . In the present proband, H. pylori gastritis may have promoted the downregulation of the second CDH1 allele. The proband's grandfather and grandmother were both healthy when they died in their 80s. Their lack of gastric cancer may be explained by partial penetrance. Although HDGC is inherited in an autosomal-dominant manner, the lifetime penetrance of CDH1 germline-mutation carriers is estimated at 70% (11) . Unfortunately, we were unable to obtain specimens from the proband's deceased father and uncle who died of gastric cancer 25-30 years prior to the proband's diagnosis. Although this family did not fulfill the IGCLC criteria (12), they did fit the revised criteria for CDH1 molecular genetic testing in individuals with gastric cancer (1).
In conclusion, we report a novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma of the stomach. This study demonstrates the disease-causing mechanism of this splicing mutation based on sequencing of RNA/cDNA from the patient, and emphasizes the need for functional studies using RNA samples for the accurate interpretation of any splicing variant detected by DNA sequencing.
MATERIALS AND METHODS
Sequence analysis
Genetic analysis was performed on the patient after obtaining written informed consent. Genomic DNA was extracted from peripheral blood leukocytes using the Wizard Genomic DNA Purification kit according to the manufacturer's instructions (Promega, Madison, WI, USA). All of the coding exons and flanking intronic regions of the CDH1 gene were amplified using primer sets designed by the authors (available upon request). PCR was performed using a thermal cycler (Model 9700; Applied Biosystems, Foster City, CA, USA). Cycle sequencing was performed on an ABI Prism 3100 Genetic Analyzer using the BigDye Terminator Cycle Sequencing Reaction Kit (Applied Biosystems). For RNA/cDNA analysis, fresh peripheral blood samples containing EDTA from the patient were collected. RT-PCR was performed in 2 steps. First, cDNA was produced from total RNA using the RevertAid First Strand cDNA Synthesis kit (Fermentas, Hanover, MD, USA) with random hexamer primers according to the manufacturer's protocol. In the second step, PCR was performed using sequence-specific primers designed by the authors that annealed to the beginning of exon 3 and to the end of the exon 8/9 junction. For RT-PCR analysis, the following primers were used: exon 3 forward, 5'-CCT GGG ACT CCA CCT ACA GA-3', and exon 8/9 reverse, 5'-TTG TAC GTG GTG GGA TTG AA-3'. For RT-sequencing analysis, the following primers were used: exon 3 forward, above; exon 6 reverse, 5'-GGA TGA CAC AGC GTG AGA GA-3'; exon 5 forward, 5'-ACC CCC TGT TGG TGT CTT TA-3'; and exon 8 reverse, 5'-CAG CTG TTG CTG TTG TGC TT-3'. We sequenced the mutation site in genomic DNA samples isolated from 96 normal healthy volunteers to show it was not a polymorphism.
Bioinformatic analysis
The CDH1 c.833-2A＞G variant was analyzed in silico for 3' splice sites using NNSplice (www.fruitfly.org/seq_tools/splice.html), GeneSplicer (http://cbcb.umd.edu/software/GeneSpli cer), Human Splicing Finder (http://www.umd.be/HSF/), MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_s-coreseq.html), NetGene2 (www.cbs.dtu.dk/services/NetGene-2), and Alamut version 1.5 (Interactive Biosoftware, Rouen, France). In each case, the software's default thresholds were used.
